The German vaccine company, CureVac, plans to raise funds by selling shares in an initial public offering in the NASDAQ market in the United States next month.
According to Reuters, a German Finance Ministry document showed that the German government intends to hold about 23 percent of CureFac unlisted to help fund the company's activities to continue developing a vaccine for Covid disease. -19 caused by the emerging corona virus.
The Finance Ministry said in a letter to the Parliament’s Budget Committee dated June 15 that it (Cure FAC) currently has significant capital requirements and plans to offer shares in Nasdaq market in New York in July 2020.
Analysts say that European biotechnology companies prefer NASDAQ because the American capital market has a large number of investors specialized in the biomedical companies sector.
